We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01225224
First Posted: October 20, 2010
Last Update Posted: October 20, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Astellas Pharma Inc
  Purpose
A study to evaluate the safety, tolerability and PK profiles of single and multiple doses of ASP015K in healthy nonelderly men.

Condition Intervention Phase
Healthy Volunteer Pharmacokinetics of ASP015K Drug: ASP015K Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Phase I Study of ASP015K: Single-Dose and Multiple-Dose Oral Administration in Healthy Nonelderly Men

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Safety evaluated by the incidence of AE, vital signs , standard 12-lead ECG and Laboratory tests [ Time Frame: For 48 hours after administration ]

Secondary Outcome Measures:
  • Plasma unchanged drug concentration [ Time Frame: For 48 hours after administration ]
  • Urinary unchanged drug concentration [ Time Frame: For 48 hours after administration ]
  • Transcription factor phosphorylation level [ Time Frame: For 48 hours after administration ]

Enrollment: 72
Study Start Date: November 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ASP015K Single Japanese Group Drug: ASP015K
oral
Experimental: ASP015K Single Caucasian Group Drug: ASP015K
oral
Placebo Comparator: Placebo Single Japanese Group Drug: Placebo
oral
Placebo Comparator: Placebo Single Caucasian Group Drug: Placebo
oral
Experimental: ASP015K Multiple Group Drug: ASP015K
oral
Placebo Comparator: Placebo Multiple Group Drug: Placebo
oral

Detailed Description:
This study consists of two parts; single and multiple administration parts. In single administration part, multiple dose levels of ASP015K or placebo are administered to Japanese and Caucasian men to evaluate whether there is ethnic differences in the pharmacokinetics and pharmacodynamics of ASK015K. In multiple administration part, drugs are administered only to Japanese volunteers.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy judged by the investigator or subinvestigator on the basis of physical examination and all test results
  • Weight

    • Japanese: ≥ 50.0 kg to < 80.0 kg
    • Caucasians: ≥ 50.0 kg to < 100.0 kg
  • BMI

    • Japanese: ≥ 17.6 kg/m2 to < 26.4 kg/m2
    • Caucasians: ≥ 18.0 kg/m2 to < 30.0 kg/m2
  • Written informed consent obtained from the subject personally

Exclusion Criteria:

  • Administered drug in another clinical study or a post-market clinical study in the 120 days prior to the study
  • Collection of 400 mL of whole blood within 90 days prior to the study, 200 mL of whole blood within 30 days prior to the study or blood components within 14 days prior to the study
  • Received or is scheduled to receive drug treatment within 7 days prior to the drug administration
  • A history of drug allergies
  • Upper gastrointestinal symptoms, e.g., nausea, vomiting or stomachache, within 7 days prior to the drug admission
  • Concurrent or previous liver disease, e.g., viral hepatitis or drug-induced hepatic injury
  • Concurrent or previous heart disease, e.g., congestive heart failure, angina pectoris or arrhythmias requiring treatment
  • Concurrent or previous kidney disease, e.g., acute renal failure, glomerulonephritis or interstitial nephritis (except for previous urinary calculus)
  • Concurrent or previous cerebrovascular disease, e.g., cerebral infarction
  • Concurrent or previous malignancy
  • Concurrent or previous active or recurrent infection, e.g., hepatitis B, hepatitis C or syphilis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01225224


Locations
Japan
Kyushu, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Chair: Use Central Contact Astellas Pharma Inc
  More Information

Responsible Party: Director, Astellas Pharma, Inc
ClinicalTrials.gov Identifier: NCT01225224     History of Changes
Other Study ID Numbers: 015K-CL-HV03
First Submitted: October 19, 2010
First Posted: October 20, 2010
Last Update Posted: October 20, 2010
Last Verified: October 2010

Keywords provided by Astellas Pharma Inc:
ASP015K
Ethnic difference

Additional relevant MeSH terms:
Niacinamide
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs